Foghorn Therapeutics (FHTX) CMO receives 300,000 stock options at $5.71

Rhea-AI Filing Summary

Foghorn Therapeutics Inc. reported that its Chief Medical Officer, Alfonso Quintas-Cardama, received a grant of stock options on January 30, 2026. The award covers 300,000 stock options with an exercise price of $5.71 per share.

The options relate to common stock and are held directly. Vesting is structured so that 25% of the underlying shares vest on January 30, 2027, with the remaining options vesting at 6.25% of the underlying shares on the first day of each calendar quarter until fully vested. The options expire on January 29, 2036 if not exercised.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Cardama Alfonso Quintas

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock option (right to buy)	300,000	$5.71	$1.71M

Holdings After Transaction: Stock option (right to buy) — 300,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cardama Alfonso Quintas

(Last) (First) (Middle)

99 COOLIDGE AVENUE

SUITE 500

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Foghorn Therapeutics Inc. [ FHTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/30/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$5.71	01/30/2026		A		300,000		(1)	01/29/2036	Common Stock	300,000	$5.71	300,000	D

Explanation of Responses:

1. The option vests as to 25% of the underlying shares of common stock on January 30, 2027, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter.

Remarks:

	/s/ Michael LaCascia, Attorney-in-Fact for Alfonso Quintas-Cardama	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Foghorn Therapeutics (FHTX) report on this Form 4?

Foghorn Therapeutics reported a stock option grant to its Chief Medical Officer, Alfonso Quintas-Cardama. He received options to acquire 300,000 shares of common stock at an exercise price of $5.71 per share under a long-term incentive structure.

How many FHTX stock options were granted to Alfonso Quintas-Cardama?

The filing shows a grant of 300,000 stock options to Alfonso Quintas-Cardama. These options give him the right to buy 300,000 shares of Foghorn Therapeutics common stock, subject to the vesting schedule and an exercise price of $5.71 per share.

What is the exercise price and expiration date of the FHTX options granted?

The stock options have an exercise price of $5.71 per share and expire on January 29, 2036. If not exercised by that date, the right to purchase the underlying Foghorn Therapeutics common shares will lapse according to the terms disclosed.

How do the FHTX stock options granted to the CMO vest over time?

The options vest as to 25% of the underlying common shares on January 30, 2027. After that, they continue vesting at 6.25% of the underlying shares on the first day of each calendar quarter until the entire 300,000-share grant is fully vested.

Does Alfonso Quintas-Cardama hold the reported FHTX options directly or indirectly?

According to the filing, the 300,000 stock options are held directly by Alfonso Quintas-Cardama. There is no indication in the provided footnote of any trust, partnership, or other entity having separate voting or investment authority over these derivative securities.